Business Wire - June 16, 2005
The address marks the first time Xenomics will present data to the research community regarding use of its proprietary Tr-DNA technology platform in detection of infectious diseases, such as HIV and tuberculosis (TB).
"Acceptance to deliver this presentation at the AACC is an important step in Xenomics' business and scientific strategy to create a new category of extremely powerful but completely safe and totally non-invasive diagnostic tests based on our proprietary Tr-DNA technology platform," said Dr. Randy White, CEO of Xenomics. "This is the first time we will present data on our progress to develop tests for infectious disease to the worldwide scientific community."
Xenomics is using its Tr-DNA platform to develop a number of completely safe, totally non-invasive, but powerful medical diagnostic tests for a range of infectious diseases, cancer, fetal genetic abnormalities and other medical applications. The Xenomics presentation will be delivered by Dr. Angela Cannes, director at the SpaXen Italia laboratory, a joint venture between Xenomics and the National Institute for Infectious Diseases in Rome, Italy. Xenomics and SpaXen are conducting research and development into applications of its Tr-DNA to create a new generation of non-invasive detection tests for infectious disease, including HIV, TB and multiple drug-resistant TB.
"The presentation at AACC enables us to debut our diagnostic data for the benefit of leading researchers in the field of infectious disease diagnostics, particularly HIV and TB, where we are making important progress toward the creation of highly accurate but completely non-invasive diagnostic tests that we believe have the potential to provide very important contributions to health care and the multi-billion-dollar molecular diagnostics industry," said Dr. David Tomei, Xenomics Chairman and scientist in charge of SpaXen.
Xenomics' prototype HIV and TB tests are further distinguished by their ability to simultaneously detect HIV and TB in a single urine sample. This is significant for treatment of AIDS patients, for whom TB is a common opportunistic co-infection. The sensitivity of Xenomics' technology may hold important implications for the improved treatment of residual HIV infections where the viral load is barely detectable or not detectable at all.
Xenomics' mission is to create and market innovative medical diagnostic tests based on its proprietary Tr-DNA technology. The tests involve the analysis of fragments of DNA that move from the blood stream through the kidneys, where they accumulate in urine. Xenomics' scientists were the first to discover the existence of Tr-DNA.
The AACC meeting is scheduled to be held July 24-28 at the Orange County Convention Center in Orlando, Florida. Xenomics will be joined at the AACC conference by leading researchers and innovative biomedical companies at a meeting expected to draw thousands of laboratory scientists, industry professionals, investors and major media outlets. Last year's meeting, held in Los Angeles, set new records for the number of participants at more than 19,000, plus hundreds of exhibition booths, according to organizers.
About the Annual Meeting of the American Association for Clinical Chemistry
The joint meeting of the XIX International Congress of Clinical Chemistry and the 2005 Annual Meeting of the American Association for Clinical Chemistry will be held in Orlando, Florida, USA. The meeting will be held at the Orange County Convention Center. For more information, please visit http://www.aacc.org .
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
CONTACT: Xenomics, Inc.
Randy White, 212-297-0808
or
Trilogy Capital Partners, Inc. (Investor Relations)
Paul Karon, 800-342-1467
paul@trilogy-capital.com
SOURCE: Xenomics, Inc.
050616
BW050615
Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .